Header

UZH-Logo

Maintenance Infos

Immunotherapy for glioblastoma: quo vadis?


Weller, Michael; Le Rhun, Emilie (2019). Immunotherapy for glioblastoma: quo vadis? Nature Reviews. Clinical Oncology, 16(7):405-406.

Abstract

Glioblastoma remains essentially incurable, and new therapeutic approaches are urgently needed. Now, the findings of three serial tissue-based studies suggest that immune-checkpoint inhibition can modify the glioblastoma microenvironment. Following these encouraging observations, the results of two phase III trials of immune-checkpoint inhibition in newly diagnosed glioblastoma, with larger cohorts of patients, are eagerly anticipated.

Abstract

Glioblastoma remains essentially incurable, and new therapeutic approaches are urgently needed. Now, the findings of three serial tissue-based studies suggest that immune-checkpoint inhibition can modify the glioblastoma microenvironment. Following these encouraging observations, the results of two phase III trials of immune-checkpoint inhibition in newly diagnosed glioblastoma, with larger cohorts of patients, are eagerly anticipated.

Statistics

Citations

Dimensions.ai Metrics
8 citations in Web of Science®
8 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

99 downloads since deposited on 21 Nov 2019
65 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Oncology
Language:English
Date:July 2019
Deposited On:21 Nov 2019 14:16
Last Modified:29 Jul 2020 11:35
Publisher:Nature Publishing Group
ISSN:1759-4774
OA Status:Green
Publisher DOI:https://doi.org/10.1038/s41571-019-0195-3
PubMed ID:30867572

Download

Green Open Access

Download PDF  'Immunotherapy for glioblastoma: quo vadis?'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 96kB
View at publisher